The Menarini Group, an Italy-based pharmaceutical and diagnostics company, announced on Thursday that it has received marketing authorisation from the European Commission for ELZONRIS (tagraxofusp) as monotherapy intended for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
This approval follows the positive opinion received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on the outcome of the clinical trial conducted in patients with treatment-naïve or previously-treated BPDCN.
The product has received orphan designation in Europe, and is now the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy in Europe to address this high unmet medical need.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval